Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice

Abstract

Depression found in Parkinson disease (PD) usually responds to selective serotonin reuptake inhibitors (SSRIs). Drugs that modify experimental neuroleptic catalepsy (NC) might affect extrapyramidal symptoms in PD. Therefore, the effects of SSRIs on NC were tested in mice, 26-36 g, separated by sex. Catalepsy was induced with haloperidol (H; 1 mg/kg, ip) and measured at 30-min intervals using a bar test. An SSRI (sertraline, ST; paroxetine, PX; fluoxetine) or vehicle (C) was injected ip 30 min before H. Dunnett's test was used for comparison of means. ST (1-5 mg/kg) or PX (1-5 mg/kg) attenuated NC, with a similar inhibition found in both sexes (5 mg/kg, 180 min: ST -males: 124 ± 10 vs 714 ± 15 s in C; females: 116 ± 10 vs 718 ± 6 s in C; PX -males: 106 ± 10 vs 714 ± 14 s in C; females: 102 ± 10 vs 715 ± 14 s in C). At 0.3 mg/kg, neither of these drugs affected NC. Fluoxetine (1-25 mg/kg) also inhibited catalepsy, although the effect was not dosedependent; no differences were observed between males and females (5 mg/kg, 180 min: males, 185 ± 14 vs 712 ± 14 s in C; females, 169 ± 10 vs 710 ± 19 s in C). For these SSRIs, maximal inhibition of NC was obtained with 5 mg/kg, 180 min after H. These results are consistent with the hypothesis that serotonergic mechanisms modulate nigrostriatal transmission, and suggest that SSRIs are possibly safe in depressive PD patients.

2,5-Dimethoxy-4-iodoamphetamine (DOI) Inhibits Δ9-Tetrahydrocannabinol-Induced Catalepsy-Like Immobilization in Mice

“…For example, selective 5-HT-reuptake inhibitors (SSRIs) attenuate haloperidolinduced catalepsy in mice (6). In addition, the 5-HT 1A -receptor agonists 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and buspirone and the 5-HT 2A/ 2C -receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) attenuate D 2 -receptor-mediated catalepsy (7 -11).…”

Antidepressant Activity of Methanolic Extract of Foeniculum Vulgare (Fennel) Fruits in Experimental Animal Models

“…Group III served as standard group that received 5mg/kg flouxetine, i.p (Pires at al., 2005) and haloperidol (1mg/kg, i.p). Group IV served as drug treated group that received MEFV (500mg/kg, p.o) and haloperidol (1mg/kg, i.p).…”

Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine

“…Ja¨rbe et al (2002) have shown that systemic administration of rimonabant (a synthetic cannabinoid CB 1 receptor) has reversed the effect of systemic administration of D 9 -THC completely (Ja¨rbe et al, 2002). As we know reserpine blocks the ability of aminergic transmitter vesicles to be reuptaked and restore dopamine, norepinephrine and serotonine, incomplete reverse of ACPA effects can be related to interfering of other neurotransmitters such as dopamine or serotonine (Pires et al, 2005). Piers et al in 2005 has demonstrated a role for serotonine and it's receptors in cannabinoids induced catalepsy.…”